AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on November 25, 2019

November 21, 2019 GMT

PETACH TIKVA, Israel--(BUSINESS WIRE)--Nov 21, 2019--

Can-Fite BioPharma Ltd. (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced its CEO Pnina Fishman Ph.D. will share insight into the Company’s recent developments during an investor webinar on Monday, November 25, 2019 at 11:00 a.m. ET. A live Q&A session with Dr. Fishman will follow her presentation.

To join the Can-Fite webinar, please register via the following link: https://www.redchip.com/corporate/webinar_register/49

The webinar will be accessible through the News/Events section of Can-Fite’s website at www.canfite.com, where it will also be archived for a period of time.

Questions can be pre-submitted to victor@redchip.com or during the event.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company’s lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite’s liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date. For more information please visit: www.can-fite.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191121005458/en/

CONTACT: For inquiries about the webinar, please contact:

RedChip Companies, Inc.

Victor Roberts

407-571-0909

victor@redchip.comCompany Contact:

Can-Fite BioPharma

Motti Farbstein

info@canfite.com

+972-3-9241114

KEYWORD: UNITED STATES NORTH AMERICA ISRAEL MIDDLE EAST NEW YORK

INDUSTRY KEYWORD: FINANCE FDA DIABETES CLINICAL TRIALS PROFESSIONAL SERVICES BIOTECHNOLOGY HEALTH PHARMACEUTICAL ONCOLOGY

SOURCE: Can-Fite BioPharma Ltd.

Copyright Business Wire 2019.

PUB: 11/21/2019 07:00 AM/DISC: 11/21/2019 07:01 AM

http://www.businesswire.com/news/home/20191121005458/en